Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

News feed

UMMC may buy Yuzhuralzoloto

10/1/25 UGLD

Etalon shareholders approved an additional issue to purchase Business-Nedvizhimost JSC

9/30/25 ETLN

Magnit extended the REPO of quasi-treasury shares

9/30/25 MGNT

KEMZ has agreed to supply machines to Belarus

9/30/25 KEMZP

HeadHunter will create a section about working in the North Caucasus

9/30/25 HEAD

Shareholders of Novorossiysk Bakery Products Plant approved dividends

9/30/25 NKHP

X5 lowered its profitability forecast

9/30/25 X5

VTB has completed the placement of an additional issue

9/30/25 VTBR

Lenta has started using robots to transport pallets.

9/30/25 LENT

Pyaterochka has opened a jubilee store in the Far East

9/30/25 X5